Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price dropped 0.6% on Monday . The stock traded as low as $25.47 and last traded at $25.50. Approximately 33,055,417 shares changed hands during trading, a decline of 12% from the average daily volume of 37,577,760 shares. The stock had previously closed at $25.64.
Wall Street Analysts Forecast Growth
PFE has been the topic of several recent analyst reports. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Guggenheim reaffirmed a "buy" rating and set a $33.00 target price on shares of Pfizer in a research report on Monday, February 10th. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Finally, Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.
Read Our Latest Report on PFE
Pfizer Stock Down 0.1 %
The business has a 50-day simple moving average of $26.28 and a two-hundred day simple moving average of $27.44. The company has a market cap of $146.52 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 0.63 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the firm earned $0.10 earnings per share. The business's quarterly revenue was up 24.7% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.65%. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer's previous quarterly dividend of $0.42. Pfizer's payout ratio is currently 121.99%.
Insider Buying and Selling at Pfizer
In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company's stock.
Hedge Funds Weigh In On Pfizer
Several large investors have recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $27,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $28,000. Finally, Gladius Capital Management LP grew its stake in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 38,015 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
